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Human porphobilinogen deaminase (PBGD), the third enzyme in the heme pathway, 
catalyzes four times a single reaction to convert porphobilinogen into hydroxymethylbilane. 
Remarkably, PBGD employs a single active site during the process, with a distinct yet 
chemically equivalent bond formed each time. The four intermediate complexes of the 
enzyme have been biochemically validated and they can be isolated but they have never 
been structurally characterized other than the apo- and holo-enzyme bound to the cofactor. 
We present crystal structures for two human PBGD intermediates: BGD loaded with the 
cofactor and with the reaction intermediate containing two additional substrate pyrrole rings. 
These results, combined with SAXS and NMR experiments, allow us to propose a 
mechanism for the reaction progression that requires less structural rearrangements than 
previously suggested: the enzyme slides a flexible loop over the growing-product active site 
cavity. The structures and the mechanism proposed for this essential reaction explain how a 
set of missense mutations result in acute intermittent porphyria. 
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The linear tetrapyrrole hydroxymethylbilane (HMB, also named pre-uroporphyrinogen) is the 
precursor of a variety of essential metabolites including heme, chlorophylls and cobalamin. 
In particular, the heme group acts as a prosthetic addition to many enzymes, transporters, 
and receptors including hemoglobin, myoglobin, catalases, peroxidases, cytochromes P450, 
and in sensor proteins for diatomic gases such as O2 or NO [1]. There are three pathways to 
make heme [2] yet, in eukaryotes, heme synthesis appears to follow the protoporphyrin 
pathway [3]. Heme synthesis is accomplished by the sequential action of several enzymes 
(eight in humans, mainly expressed in liver and in erythroid cells). Porphobilinogen 
deaminase (PBGD, EC 2.5.1.61) is the third enzyme of this biosynthetic route, catalysing the 
condensation of four units of porphobilinogen (PBG) to yield HMB, which is the precursor to 
all the tetrapyrroles. Inborn errors in any of these enzymes ultimately lead to severe 
metabolic disorders family termed as porphyrias [4]. Specifically, mutations in HMBS are 
responsible for Acute Intermittent Porphyria (AIP) with more than 400 pathogenic mutations 
described so far (including nonsense, missense and other mutations) [5,6]. 
PBGD is a monomeric enzyme, highly conserved across different species, with a molecular 
mass ranging between 34 to 45 kDa. ApoPBGD is thermodynamically unstable and it 
spontaneously and covalently attaches a dipyrromethane cofactor (DPM) from the reaction 
of the apo-enzyme with hydroxymethylbilane to generate the active holoenzyme in its ES2 
form [7,8]. Human PBGD is comprised of 3 distinct domains [9] and shares over 45% 
primary sequence identity with its counterparts from E. coli and others [10]. Two isoforms 
have been reported: the 44-kDa ubiquitous (housekeeping) enzyme (PBGD1) and the 42-
kDa erythrocyte-specific enzyme (PBGD2) [11]. The ubiquitous PBGD1 has 17 extra 
residues in the N-terminal region when compared to erythrocytic PBGD2. The role for this 
tail in the N-terminal region is unclear but experimental evidence demonstrates that such 
residues remain unstructured, do not alter the overall fold, nor the catalytic activity, nor the 
enzyme's stability [12].  
PBGD catalyses the formation of HMB by incorporating four units of PBG in a multistep 
reaction (Fig. S1) [13]. Reaction initially involves deamination of the PBG, followed by the 
attachment of the resulting azafulvene to the free alpha position. The DPM cofactor serves 
as a primer for the loading of further PBG molecules and, remarkably, holoPBGD uses the 
same acidic residue (D99 in the human sequence) for the pyrrole condensation (four times), 
repeating reactions where each intermediate of the polypyrrole elongation remains 
covalently attached to the DPM cofactor [14]. The resulting linear hexapyrrole is unstable 
and cleaves off through an unknown mechanism to yield the linear tetrapyrrole HMB product, 















Two different mechanisms have been proposed to explain how the enzyme deals with the 
growing oligopyrrole chain during catalysis and how the cleavage of the product occurs 
[15,16]. The first one assumes that the enzyme structure is flexible, such that the active site 
is opened for the entry of a new PBG molecule and closed during the ring fusion. Such 
opening and closing of the active site in human PBGD would be accomplished by movement 
of protein domains around proposed hinge regions (S96, H120, L238) [9]. The second 
mechanism speculates that at least four pyrroles could be accommodated without significant 
movement of the protein domains. Rotation of the cofactor around the covalent bond, linking 
the methylene C atom of the C1 pyrrole with the Cys261 S atom would cause the C1 and C2 
rings to vacate their respective binding sites and potentially allow another pyrrole moiety to 
bind at the catalytic centre of the enzyme. The cofactor movement would be aided by the 
presence of two almost completely invariant glycine residues [17]. 
To date, 14 crystal structures of the protein are available in the Protein Data Bank (2 of H. 
sapiens, 5 of E. coli, 5 of B. megaterium, 1 of A. thaliana and 1 of V. cholerae) [9,10,17-20]. 
Despite these efforts, the structures are either the apo- (50V4, D82A-PBGD of B. 
megaterium) or the holoPBGD and they provide little information on the intermediate 
catalytic stages of PBGD. Here, we present crystal structures of PBGD loaded with the 
cofactor (Eholo, 2.78 Å, PDB-ID: 5M7F) and PBGD with two additional substrate rings (ES2, 
2.73 Å, PDB-ID: 5M6R). Our structures, supported by additional Small Angle X-ray 
Scattering (SAXS) and NMR experiments, allow us to propose a mechanism for the reaction 
coordinate, with fewer enzyme structural changes than previously suggested, mostly 
effected by a change in volume at the active site. The latter change in turn results from a 
substrate-induced rearrangement of a flexible loop (R255-V263) sliding over the active site 
during reaction progression, in basic agreement with the static hypothesis. The large number 
of AIP-causing mutations occurring in this loop confirms the key relevance of this structural 
element not only for the reaction but also in disease.  
 
 
Materials & Methods 
Protein expression and purification. Freshly transformed E. coli BL21 (DE3) cells were 
used for protein expression. Cells to produce proteins for crystallization tests were grown in 
regular LB media, whereas cells to produce protein samples required for NMR experiments 
included ammonium chloride as the sole sources of nitrogen for protein synthesis. Protein 
purification was achieved as previously described [21], with the following modifications: the 
fractions containing pure PBGD were then loaded to an anion exchange chromatography 















complexes were eluted with a linear gradient of buffer B; 0-30% in 35 CV or 0-20% in 50CV 
for respectively, Q or MonoQ column. Separated complexes, whose concentration were 
measured by UV-vis spectrometry at 280 nm, can be used immediately or flash frozen in 1 
ml aliquots and stored in -80 ºC. 
SAXS data collection and analysis. Synchrotron SAXS data were collected on beamline 
BM29 at ESRF (Grenoble, France) with a 2D detector (Pilatus 1M) over an angular 
range qmin = 0.01 Å
−1 to qmax = 0.5 Å
−1. X-ray scattering patterns were recorded for PBGD 
reaction intermediates at the concentration of 1.92 and 6.40 mg/mL (Eholo), 2.63 and 5.24 
mg/mL (ES), 2.10 and 4.26 mg/mL (ES2), 1.53 and 3.43 mg/mL (ES3) in standard size 
exclusion chromatography buffer (20mM Tris-HCl pH 8.5, 40mM NaCl). In order to generate 
an ab initio model, ten runs of DAMMIN[22] were performed, and after averaging and filtering 
a representative bead model with 732 beads was obtained. Superposition of the bead model 
on the relaxed crystallographic PBGD (3ECR) structure was carried out using the program 
SUPCOMB [22]. 
Crystallization and Structure Determination. Diffraction-quality PBGD crystals for 
holoenzyme (Eholo, PBGD2) and one of the reaction intermediate complexes (ES2, PBGD1) 
were obtained by hanging-drop vapour diffusion at 21 °C in a solution containing 0.1 M 
sodium cacodylate pH 6.5, 0.2 M sodium chloride, 2 M ammonium sulphate and 0.1 M Na 
HEPES pH 7.2, 0.9 M Na dihydrogen phosphate/0.9 M K dihydrogen phosphate, 
respectively. Individual crystals were cryo-protected by a brief soak in mother liquor 
supplemented with 25 % glycerol and flash frozen in liquid nitrogen.  Diffraction data were 
remotely collected at a wavelength of 0.972422 Å at the ID23-1 beamline at the ESRF 
synchrotron centre (Grenoble, France). Diffraction data were processed using the XDS and 
the Aimless programs [23]. Molecular replacement was carried out by the MOLREP program 
with E. coli PBGD (PDB ID: 3ECR) as the search model. Refinement was performed using 
the autoBUSTER computer program [24] and iterative cycles of model building achieved 
using COOT from the CCP4 suite [25]. 
NMR spectroscopy. 1H,15N-HSQC experiments were recorded at 37 ºC on an 800 MHz 
Bruker Advance III spectrometer from 15N isotopically enriched protein samples in PBGD 
purification buffer A. 1024x200 points where collected and water suppression was achieved 
using WATERGATE. The data were processed using NMRPipe [26] software and in-house 
built scripts. Processed data were analysed with NMRDraw. 
Docking simulations. A standard docking procedure was used for a rigid protein and a 















centred on macromolecule of 126, 126, and 126 points in x, y, and z directions was built with 
a grid spacing of 0.458 Å. The default settings were used for all other parameters. From the 
resulting ligand clusters those with best (lowest) binding energies and localized within the 
active centre area were analysed for hydrogen bonding using AutoDockTools and Discovery 
Studio Visualizer 4.5.  
Molecular Dynamics simulations. MD simulations (for structure relaxation before fitting 
model to the SAXS data) were performed with the NAMD2 program along with the 
CHARMM27 force field. Simulations were carried out in the constant volume-constant 
temperature (NVT) ensemble with the Leapfrog Verlet integrator employing an integration 
time step of 2 fs. A protein was solvated in a water sphere and the system was neutralized 
with NaCl. Covalent bonds between hydrogen atoms and heavy atoms were constrained by 
means of the RATTLE algorithm. A switching function was used to truncate the non-bonded 
interactions (Van der Waals and electrostatics) in the cut-off distance of 12 Å. The 
conjugated gradient method of minimization was used to relax the structure before the 
production for 5000 steps of force evaluations. MD run was performed for 17 ns (excluding 
the minimization). Coordinates were written to trajectory file every 50 or 100 steps and 
energy value were output every 10 steps. 
 
Results 
Isolation of human PBGD reaction intermediates. Investigation of the reaction 
mechanism requires the isolation of the PBGD reaction intermediates, which is a challenging 
task because each such species shows inherent reversibility, thus affecting the integrity of 
each isolated form over time. To address this issue, reaction intermediates of human PBGD 
(PBGD1 or PBGD2) were heterologously expressed in E. coli and purified as previously 
described [27] but adapting a protocol to ensure maximum purity and stability of the isolated 
intermediates (see Materials & Methods). Specifically, no ammonium ions were present at 
any time during the purification, not to shift the reaction balance to Eholo; and size exclusion 
chromatography was used as an early purification step, before optimizing the ion exchange 
chromatographic separation of the intermediates. As a result, five enzyme reaction 
intermediates could be isolated from each isoenzyme form, as determined by native gel 
analysis (Fig. 1). Mass spectrometry confirmed the chemical composition of each enzyme 
reaction intermediate (ESholo, ES, ES2 x2 and ES3, Fig. 1). Two ES2 intermediates can be 
separated by gel electrophoresis (Fig. 1) and ion exchange chromatography (Fig. S2), 
indicating the existence of two ES2 conformations with different solvent exposed charge. The 
purified reaction intermediates show long term stability (more than 1 month) and do not 
















Reaction intermediates do not show large conformational changes. We have used a 
set of biophysical techniques to characterize the conformational changes across the PBGD 
reaction intermediates. First, small-angle X-ray scattering (SAXS) was collected at a 
synchrotron source for each of the protein intermediates (obtained from the PBGD1 isoform). 
For all collected datasets, SAXS data is only compatible with a monomeric form of PBGD, in 
agreement with ion exchange chromatography elution profiles (Fig. S2). The low-resolution 
SAXS-derived structural models were compared to the human high-resolution structure 
(PDB-ID: 3ECR, Eholo). To that end, the 3ECR structure was completed with homology 
modelling to fill the portions missing from the crystal structure (1-20, 60-78, 361-364) and 
subjected to the MD simulations for structure relaxation (17 ns, see Star Methods section), 
while the cofactor and reaction intermediates were not included. The SAXS molecular 
shapes (colorful mesh) are in good agreement with the 3ECR structure (black cartoon) for 
Eholo, ES and ES2 reaction intermediates (Fig. 2A). The radius of gyration (Rg), estimated 
from the low-angle scattering region by a Guinier plot [28], also yields no significant 
differences among these enzyme variants (Fig. 2B and Table 1). In case of the last stage of 
reaction, before product release (PBGD ES3), SAXS reports a larger Rg value and increases 
in the maximum linear dimension Dmax and in the Chi parameter, but the 3ECR structure still 
fits the Eholo SAXS-derived low-resolution envelope rather well.  
Isotope-enriched enzyme-intermediate complexes were also analyzed by NMR 
spectroscopy. Due to the exquisite sensitivity of chemical shift to changes in the nuclear 
environment the 1H,15N-HSQC is a fingerprint spectrum for a protein, suitable to monitor its 
conformational rearrangements. The 1H,15N-HSQC spectra for the different reaction 
intermediates are very similar (Fig. 2C), with a small number of peaks showing chemical shift 
perturbation. This is the expected outcome for localized changes instead of segmental 
domain motion, agrees with the SAXS data and suggests a reaction mechanism with 
localized segmental dynamics, ruling out the domain-reorienting mechanism. To confirm this 
hypothesis and to identify the involved structural elements, high-resolution structures are 
desirable.  
 
High resolution structures for Eholo and the ES2 reaction intermediate. To maximize 
chances of obtaining diffraction-quality PBGD crystals, trials using both PBGD variants 
(PBGD1 and PBGD2) were attempted, using crystallization screens based on the conditions 
reported in the literature or commercially available screens. The temperature was also 
varied. Crystals were always grown in the dark, to prevent cofactor and substrate photo-















crystal plates that grow in tight stacks (Fig. S3). The yellow color of the crystals indicates 
partial oxidation of the polypyrrol moiety.  Out of the more than 160 crystals tested and more 
than 40 diffraction datasets collected, two crystals produced good resolution diffraction 
datasets for two reaction intermediates: Eholo (PBGD2, Fig. S4) and (ES2, PBGD1, Fig. S5).  
The diffraction data obtained from these crystals were processed to a resolution of 2.78 Å 
and 2.73 Å for Eholo and ES2-complex, respectively. The crystallographic data collection and 
refinement statistics are presented in Table 2. Both crystals belong to the monoclinic space 
group P21, with unit-cell parameters a = 70.42 Å, b = 80.95 Å, c = 76.22 Å, β = 95.70° for 
Eholo; and a = 68.91 Å, b = 81.20 Å, c = 79.69 Å, β = 93.01° for the ES2-complex. The 
Matthews coefficient[29,30], suggests that there is a single PBGD dimer per crystallographic 
asymmetric unit, with a solvent content of 57%, in both crystals. Structure solution by 
molecular-replacement used H. sapiens PBGD (PDB ID: 3ECR) as the search model. The 
final structures were validated using the MolProbity Server [31] and the final statistics were 
Rwork = 0.220 (0.260) and Rfree = 0.197 (0.246) for Eholo (ES2–complex), respectively. 
Coordinates were deposited in the PDB with the accession codes 5M7F (PBGD2:Eholo) and 
5M6R (PBGD1:ES2). 
 
Overall description of Eholo and ES2–complex and comparison with other PBGD 
structures. The human PBGD structures for Eholo and ES2–complex share the same fold, 
comprised of three α/β domains each of about 110 residues (domain 1: 1-116 and 216-239; 
domain 2: 117-215; domain 3: 240-361), linked together by flexible hinge regions (S96, 
H120, L238). Domains 1 and 2 are structurally close to periplasmic carbohydrate binding 
proteins [32]. The substrate-binding site is located in a cleft region between domains 1 and 
2, while the dipyrromethane cofactor is covalently attached to Cys261, in a loop connecting 
13 and 13 in domain 3 (residues 248-264). Residues S59–S76, previously uncharacterized 
in human (or E. coli) structures, show well defined electron density in the ES2–complex 
PBGD structure. These residues lie in a loop in the vicinity of the active site, forming a cap-
like structure that covers the entire cavity. 
Eholo is very similar to the previously elucidated human PBGD holo structures with r.m.s.d. 
values of 0.5 Å and 0.7 Å when compared 3ECR and 3EQ1 [9,10]. Such structural homology 
is largely maintained also for ES2, which compares well with 3ECR (0.8 Å) and 3EQ1 (0.9 
Å). A superposition of Eholo and ES2-complex shows their striking structural similarity, which 
is reflected in a C r.m.s.d. of 0.6 Å for the 316 common residues (Fig. 3A). The comparison 
is made with structures from different isoforms, underlining the structural/functional 
equivalence between PBGD1 and PBGD2 and we suggest that the 17 extra residues found 















enzyme. When compared domain by domain, the r.m.s.d. between Eholo and ES2 become 
0.4, 0.3 and 0.8 Å for domains 1, 2 and 3 respectively. The most noticeable changes are 
concentrated in the flexible loop that contains Cys261, located in domain 3 (Fig. 3B). In the 
ES2 structure the loop is pulled back from the active site, displacing the Cys261 covalently-
linked cofactor to a novel binding site. Such rearrangement is key for understanding the 
mechanism of substrate elongation (vide infra) but it also underlines the fact that localized 
and not domain motions govern the conformational changes from Eholo to ES2, consistent 
with the SAXS and NMR data. 
 
Structure of the active site and insights into the catalytic mechanism. In the Eholo PBGD 
structure, the dipyrromethane cofactor (pyrrole units C1 and C2, Fig. 4A) is positioned within 
a deep positively charged cleft formed between domains 1 and 2 (purple and orange 
volumes in Fig. 4E corresponding to the frontal and rear sub-cavities of the cleft). This ligand 
placement is also found in equivalent Eholo PBGD high-resolution structures and the cofactor 
is stabilized by well described interactions with surrounding residues (Fig. 4C) [10,18,33]. 
The C1 pyrrole unit is covalently attached to C261, which belongs to a loop (R255-V263) 
located in domain 3. In the ES2 PBGD structure, the R255-V263 loop pulls away from the 
active site, displacing the polypyrrole chain by about 5 Å, dragging the C1 and C2 pyrroles 
into a new pocket (expansion of the rear sub-cavity, orange in Figures 4B-D); while the S1 
and S2 units now occupy the positions the cofactor had in the Eholo structure, with the S1-S2 
pyrrole units in ES2 PBGD adopting exactly the same conformation and being stabilized by 
the same residues as the C1-C2 cofactor in Eholo PBGD. This suggests that the cofactor in 
Eholo is strongly bound and already adopts a catalytically relevant conformation. These 
observations are consistent with the large number of conserved surrounding residues and 
with the reaction's stereospecificity [34]. Yet, the ES2-complex is further stabilized by the 
extra interactions that the newly displaced C1-C2 cofactor creates with the protein at the rear 
cavity, mostly with T102, V215 and S262. Such added interactions provide a structural 
rationale for the empirical observation that ES2 is the most stable of the purified reaction 
intermediates [27,35].  
In the ES2-complex, D99, a key residue in the polypyrrole chain elongation, retains the 
hydrogen bonding with the N-H of S2 (C2 in Eholo), required for the elongation reaction, but it 
also falls at a reactive distance from the C2-S1 interface (3.8 Å to the S1 H-N), which is the 
product cleavage point (Fig. 4E-F). This proximity strongly suggests that D99 may also play 
a relevant role in the product release by catalyzing the hydrolysis reaction, in agreement with 















context of our ES2 PBGD structure, D99 is located at about 8.5 Å from the cofactor C1 ring 
(Fig. 4F), which now would become protected from hydrolysis during the elongation process.  
In Eholo the active site is large (674 Å
3, Fig. 4A) and rich in positively charged residues 
(mainly Lys and Arg residues) to compensate-for and attract the negative charges 
introduced with the ligands’ carboxylates during the elongation process. The placement of 
the cofactor and the location of D99 suggest that the PBG substrate enters the site from the 
frontal sub-cavity, as indicated by the arrow in Figure 3A. Remarkably, the displacement of 
the R255-V263 loop in the ES2 PBGD intermediate enlarges the overall cavity size to a final 
volume of 787 Å3 (Fig. 4D), creating a large empty space on the distal end of the catalytic 
site and dividing the cavity in two similar subspaces around D99: the frontal sub-cavity that 
remains largely unaltered as compared to Eholo (purple in Figures 4C,D, ES2 frontal sub-
cavity volume is 487 Å3); and the rear sub-cavity (orange in Figures 4C,D), which is very 
large for ES2 (300 Å
3) and directly produced by the loop displacement. 
To investigate which parts of the cavity are relevant for the elongation reaction, we have 
used a set of competitive inhibitors that are able to effectively block the reaction (Ki  100 
M).  Specifically, computational docking of the inhibitors into the Eholo and ES2 structures 
allows pinpointing the areas that may accommodate the substrate. As is shown in Fig. S6, 
both sub-cavities are occupied by the inhibitors in ES2, while only the frontal sub-cavity is hit 
by the inhibitors in Eholo. This is consistent with substrates approaching the active site via the 
frontal sub-cavity. Interestingly, the extended size of the rear sub-cavity in ES2 would allow 
the tetrapyrrole to adopt a different placement, in which the S2 moiety would occupy the S1 
pocket and the S1 pyrrole ring would be completely inserted into the rear sub-cavity. Such a 
conformation would ease the entrance to the S2 site of a subsequent PBG molecule which 
would then proceed to fuse with ES2 and elongate the product to ES3. Based on this 
hypothesis, a computationally-derived model of the resulting ES3 complex is shown in Fig. 
S7. Presumably, further displacement of the R255-V263 loop would enlarge the rear sub-
cavity even more so the reaction can progress towards the formation of ES4. In support of 
this model, the R26H mutant located in the frontal volume has been associated only with a 
reduced capacity to incorporate new substrate units [34]. 
 
The active-site loop is a lid for the catalytic site. The active site is partially protected by a 
flap region constituted by residues 57-74 in human PBGD, which is likely relevant in binding 
the substrate and cofactor as well as in aiding catalysis. This active-site loop is missing in all 
the deposited structures so far except in the Eholo PBGD from A. thaliana (4HTG) [17]. In this 















displays ordered electron density for the flap region. The latter was revealed to form a cap-
like structure that covers the active site. The loop in the remaining human holo-structures 
described so far is only partially ordered, with residues G60-I71 adopting -helical 
secondary structure, while the equivalent region in PBGD ID 4HTG is much more disordered 
(Fig. 3C). Interestingly, the loop in our ES2 human structure folds towards the active site, so 
that residue E73 is able to form a hydrogen bond with the propionate side chain of the C2 
ring of the growing product, ultimately stabilizing the complex. In the A. thaliana structure, 
the equivalent residue to E73 is D66, which is solvent exposed and displays no interactions, 
in agreement with the Eholo contents of that active site. 
 
Discussion 
In this contribution, we report the first medium resolution structure of a reaction intermediate 
for PBGD (ES2 of human PBGD1, PBD ID 5M6R). The combined analysis of the ES2-
complex with the structure of human Eholo PBGD2 (PBD ID 5M7F, also presented here) 
reveals that the structural changes upon polypyrrole elongation are largely constrained to the 
R255-V263 loop, refuting the hypothesis of significant domain rearrangements during the 
reaction progression up to the ES2 intermediate (Fig. 3). It is entirely plausible to suggest 
that the only significant changes in the structure during the second part of the reaction 
(formation of ES4 and product release) would also only affect to the R255-V263 loop, in 
keeping with our SAXS, NMR and gel filtration chromatography data. 
In spite of the limited extent of the reported conformational changes among the reaction 
intermediates, the progressive increase in the electrophoretic mobility observed in the native 
polyacrylamide electrophoresis (Fig. 1) and their successful ionic exchange separation (Fig. 
S2) suggest a gradual increase in net negative charge compared to that of Eapo or Eholo, as 
previously suggested [37]. As shown in Table S1, this is actually the case, and it can be 
mainly attributed to the PBGD Arg residues, which experience a large reduction in their 
solvent accessible area in ES2 as compared to Eholo, due to salt-bridge interactions with the 
negatively charged pyrrole units. 
The structures reported here provide molecular detail on how the reaction process takes 
place within the confines of a single active site. At least three previously undescribed 
observations obtained from the structures appear to be relevant for the reaction mechanism: 
i) the displacement of the R255-V263 loop, which allows reaction progression up to the ES2 
stage allocating the cofactor (C1-C2 rings) into a new pocket and extracting it from the 
catalytic pocket; ii) the displacement of the same loop generates a new internal cavity, which 















of the ligands from the catalytic residue D99 [38], which is always at reactive distance from 
the S2(C2) elongation pocket, but also close enough to the C2 ring. Therefore, we propose 
that D99 is also responsible for product release. A scheme that embraces all these features 
into a mechanistic model of reaction progression is shown in Fig. 5. In the Eholo structure, the 
catalytic site is nearby the key residue D99 and occupied by the cofactor. The entrance of 
new PBG molecules occurs through the frontal sub-cavity and is facilitated by electrostatic 
complementarity. The entrance of the PBG into the rear sub-cavity likely produces the 
cofactor shift, mediated by the displacement of the loop containing Cys261. As a result, C1 
now occupies a new pocket whilst C2 occupies the former C1 position and the new pyrrole 
unit is allocated at the condensation catalytic site. The progressive enlargement of the rear 
sub-cavity produced by the concerted R255-V263 loop displacement would allow for this 
mechanism to be repeated twice, up to the formation of the ES4 intermediate. 
A plausible mechanism for the HMB release is also shown in Fig. 5.  According to our model, 
cleavage of the bilane attached to the cofactor and polypyrrole elongation are catalyzed by 
the same aspartic acid, which is always at reactive distance from the catalytic pocket (the 
location of the next PBG unit for condensation) and from the N-H of C2 (likely, the cleavage 
point in the polymer). We hypothesize that steric tension and the proximity of the C2 ring to 
D99 may trigger the cleavage hydrolytic reaction and product release. Essentially, the 
mechanism we propose corresponds to the reverse condensation reaction mechanism, also 
involving an azafulvene intermediate. In this context, both reactions are reversible and they 
could spontaneously occur at the appropriate stage of the elongation reaction. The interplay 
between the two opposite reactions (condensation and hydrolysis) is governed by a delicate 
balance between the S2 and C2 distances to D99. According to this hypothesis, the 
condensation reaction would dominate from Eholo to ES4 due to a closer distance of D99 to 
the reaction site than to C2 (confirmed for ES2: D99 is at 2.2 Å and 3.8 Å of the N-H of S2 
and C2 respectively), with some aid from the chemical driving force of the substrate excess. 
During the elongation reaction, it is plausible that the D99(O)-C2(NH) distance shortens to 
favor the hydrolysis reaction, as reflected in the structural model for the ES3 reaction 
intermediate (Fig. S7). This feature, combined with the increasing steric tension of the 
reaction intermediate, may favor the hydrolysis reaction. The active site loop (residues 57-74 
in the human isoform) is forming a contact with the C2 ring that could presumably fine tune 
the distance between D99 and the pyrrole unit. The experimental reconstitution of Eholo 
starting from Eapo and HMB [36] supports this model. 
The reported structures also allow rationalization of the relative stability of the reaction 
intermediates. Clearly, ES2 is more stable than Eholo, because it integrally maintains the 















interactions generated between the C1/C2 pyrroles and the residues lining the new pocket. 
Consistent with these observations, the ES reaction intermediate would be more stable than 
Eholo and less stable than ES2. We predict that progression from ES2 to ES4 might generate 
further interactions between the polypyrrole and the cavity residues but likely at the cost of 
generating a tensioned and, therefore, ultimately unstable conformation. 
Last but not least, the reported structures and the proposed reaction mechanism allow 
rationalization of previously unexplained missense mutations in human HMBS that result in 
AIP. As it is common in porphyria [21], most of the 168 missense mutations reported in the 
Human Mutation Database [5] can be associated with reduced protein stability. Yet, a subset 
of the point mutations has already been associated to a loss of interactions between protein 
residues and the C1-C2 pyrrole units in the Eholo structure, affecting the stability of the 
reaction intermediates [10,39]. Here we highlight the relevance of the sliding loop, key for 
reaction elongation, which also contains seven residues (E250, A252, L254, H256, E258, 
G260 and C261) that produce AIP upon mutation. It is likely that these mutations constrain 
the loop mobility, ultimately compromising reaction progression. Furthermore, the V215M 
and V215E mutations, which would abrogate the V215-mediated stabilization of the C2 ring 
at the shifted position in the ES2 structure, also results in AIP. Other residues in the rear 
cavity are also involved in AIP upon mutation: L254, R149, A214 and Y213. These mutants 
may be amenable to stabilization by pharmacological chaperones, opening new therapeutic 
intervention avenues against the disease. 
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Figure 1. Native polyacrylamide electrophoresis for the different reaction intermediates 
isolated for human PBGD. The band downshift suggests a gradual increase in net negative 
charge as compared to Eapo. ES2 and ES2' both correspond to the reaction intermediate with 
two PBG condensed units. The presence of multiple bands probably indicates incomplete 
separation between the intermediates. The asterisk indicates the intermediate that was 
successfully crystallized. 
Figure 2. Biophysical properties of the PBGD reaction intermediates. (A) Superimposition of 
the relaxed model structure (3ECR, after 17 ns MD simulation) with the SAXS-derived low-
resolution protein volumes. (B) Fitting of the experimental scattering spectra with a simulated 
fit obtained from the relaxed structure. (C) 1H,15N-HSQC spectra for the isolated PBGD 
reaction intermediates show chemical shift perturbations consistent with localised structural 
changes. 
Figure 3. (A) Overall structure of human PBGD. Cartoon representation of human PBGD 
bound with dipyromethane cofactor (Eholo, erythrocytic PBGD isoform, green) overlaid with 
the reaction intermediate (ES2, housekeeping isoform, blue). The arrow indicates the likely 
pathway for a new PBG unit as well as the direction of the loop displacement. (B) Root mean 
square deviation values between the residues of Eholo (reference) and ES2-complex 
structures. Values below the average (r.m.s.dav = 0.434) covered with grey color. (C) 
Cartoon representation of ES2 PBGD showing the loop region covering the active site, red 
highlighted. The two orientations correspond to a 90º rotation along the ordinate reference 
axis. 
Figure 4. Active site of human PBGD. (A-B) Electron density for the cofactor/ligand in Eholo 
and ES2. The interactions between the cofactor or the reaction intermediate and the residues 
from the active site are shown in (C) and (D) for Eholo and ES2, respectively. The cavity 
volume enclosing the active site is shown in (E) and (F) for Eholo and ES2. For clarity, the 
cavity has been divided into the frontal (purple) and rear (orange) sub-cavities, as indicated. 
Distances between the catalytic residue D99 and some atoms relevant for the reaction are 
shown in (G) and (H) for Eholo and ES2-complex. 
Figure 5. Scheme showing the active site cavity as a function of the reaction progression. 
The R255-V263 loop hosts C261 which covalently binds the cofactor. The loop displaces 
during polypyrrole elongation. At all times, D99 is at reactive distance of the S2 and C2 
positions in the ES2 complex. According to our model, once the ES4 complex is reached, the 















cavities for Eholo and ES2 (dash gray line highlight) are depicted from the high-resolution 






















Table 1.  SAXS data analysis statistics 
Protein sample Rg [Å] Dmax [Å] Chi NSD
(1)
 
PBGD1 Eholo 2.39 +/- 0.01 8.38 1.094 0.8212 
PBGD1 ES 2.45 +/- 0.07 8.59 2.04 0.8169 
PBGD1 ES2 2.43 +/- 0.04 8.51 1.788 0.8117 
PBGD1 ES3 2.92 +/- 0.12 10.23 5.037 0.8114 

















Table 2. PBGD crystallographic data collection and refinement statistics 
Values in parentheses refer to the outer resolution range 
 
PDB ID 5M7F (Eholo) 5M6R (ES2) 
X-ray data collection statistics 
X-ray source ESRF ID23-1 ESRF ID23-1 
Detector Dectris Pilatus 6M-F Dectris Pilatus 6M-F 
Wavelength (Å) 0.972422 0.972422 
Space group P 1 21 1 P 1 21 1 
Cell constants 
a, b, c, α, β, γ 
70.42Å, 80.95Å, 76.22Å, 90.00º, 
95.70º, 90.00º 
68.91Å, 81.20Å, 79.69Å, 
90.00º, 93.01º, 90.00º 
Resolution limits  (Å) 80.95–2.78 (2.83–2.78) 81.20–2.73 (2.78–2.73) 
Completeness (%) 98.9 (83.1) 97.7 (65.7) 
Unique reflections measured 21353 22971 
Multiplicity 3.3 (2.6) 9.2 (3.8) 
Rmerge(I) 0.247 (1.265) 0.194 (1.377) 
CChalf 0.946 (0.477) 0.996 (0.655) 
Average I/σ(I) 3.1 (0.9) 11.7 (1.2) 
Refinement statistics 
Resolution range  (Å) 29.77–2.78 (2.92–2.78) 56.84–2.73 (2.86–2.73) 
Completeness (%) 98.5 (91.77) 95.8 (77.95) 
Unique reflections refined 
against 
21279 (2509) 22510 (2306) 
Free set 1112 (112) 1104 (127) 
R 0.222 0.200 
Rwork 0.220 (0.250) 0.197 (0.239) 
Rfree 0.260 (0.301) 0.246 (0.289) 
RMSD bond lengths (Å) 0.01 0.01 







Residues modelled (range) A: 20–57, 75–353, B: 20–56, 
75–353 
A: 18–357, B: 18–61, 76–353 
Waters modelled 49 23 
Non-protein molecules 2 DPM, 6 SO4 2 7J8, 3 PO4, 1 EPE 
Total number of atoms 10034 10597 
Average B, all atoms (Å
2
















 First crystal structure of a PBGD reaction intermediate.  
 Structural data reveal molecular basis for tetrapyrrole elongation by 
PBGD.  
 Identification of a mobile loop and a cavity of variable size, key for 
reaction. 
 Rationalization of a set of mutations causing acute intermittent 
porphyria. 
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